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conditions, most of which are inherited. Although
individual rare kidney diseases raise speciﬁc issues, as a
group these rare diseases can have overlapping challenges
in diagnosis and treatment. These challenges include small
numbers of affected patients, unidentiﬁed causes of
disease, lack of biomarkers for monitoring disease
progression, and need for complex care. To address
common clinical and patient issues among rare kidney
diseases, the KDIGO Controversies Conference entitled,
Common Elements in Rare Kidney Diseases, brought
together a panel of multidisciplinary clinical providers and
patient advocates to address ﬁve central issues for rare
kidney diseases. These issues encompassed diagnostic
challenges, management of kidney functional decline and
progression of chronic kidney disease, challenges in clinical
study design, translation of advances in research to clinical
care, and provision of practical and integrated patient
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796addressing these challenges was developed and is
presented here.
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T he deﬁnition of rare diseases varies across the world. InEurope, a disease or disorder is deﬁned as rare when theprevalence is <1 in 2000 individuals; whereas in the
USA, the designation of rare disorder applies when <200,000
Americans are affected. Rare kidney diseases encompass$ 150
different conditions. The majority are inherited,1 while others,
such as the primary glomerulonephritides, have complex eti-
ologies. For inherited kidney disorders, diagnosis, manage-
ment, and treatment are complex, especially when they are
associated with multisystem complications. Patients often
spend years visiting multiple health care providers before
receiving an accurate diagnosis. Advances in kidney replace-
ment therapy and its increased access allow prolonged patient
survival, yet often with a poor quality of life. In particular,
children born with severe congenital nephropathies face a high
likelihood of altered physical, cognitive, and psychosocial
development.2Kidney International (2017) 92, 796–808
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hindered by several factors, including unresolved genetic de-
fects, lack of biomarkers to monitor disease progression,
heterogeneous clinical phenotypes, and outdated diagnostic
classiﬁcations that do not reﬂect underlying pathophysiolog-
ical mechanisms.1,3 Many initiatives have focused on rare
kidney diseases, and regulations have been created to promote
the development of therapies, organize optimal health care
systems, and encourage research. Patient organizations have
also taken a leading role in these matters. Together, techno-
logical advances and organized advocacy have helped enhance
understanding of the clinical, genetic, and mechanistic issues
in many inherited kidney disorders.
To address common clinical and patient issues among rare
kidney diseases, Kidney Disease: Improving Global Outcomes
(KDIGO) convened a global, multidisciplinary Controversies
Conference to address 5 central issues in rare kidney diseases:
diagnostic challenges, management of kidney functional
decline and progression of chronic kidney disease (CKD),
challenges in clinical study design, translation of advances in
research to clinical care, and provision of practical and inte-
grated patient support. The deliberations from this confer-
ence are now summarized here with additional ancillary
information available online at http://kdigo.org/conferences/
common-elements/.
DIAGNOSTIC CHALLENGES
The growing use of next-generation sequencing techniques is
expected to increase diagnostic accuracy for rare kidney dis-
eases, help decipher the molecular mechanism of disease,
facilitate genetic counseling, and offer possibilities for carrier
testing.4 The burgeoning wealth of genetic and molecular
information has evoked new challenges, such as the need for
more sophisticated bioinformatic analytic tools and algo-
rithms. Additionally, the changes in molecular techniques and
interpretations are creating novel ethical, legal, and social
challenges.5,6 Even for well-deﬁned disorders, barriers to
generalized use of genetic testing may persist due to high cost
and long turnaround times, insufﬁcient genetic literacy, as-
sumptions that establishing a genetic diagnosis will impact (or
not) clinical management, and differences in accessibility and
insurance coverage.7 These factors are particularly challenging
in settings with limited resources. Policies to promote clini-
cally relevant genetic testing and adequate integration of ge-
netic information are needed.8
Genetic testing in diagnosis
In diagnosing rare kidney diseases, careful phenotyping
encompassing physical examination, patient history,
biochemical analysis, and pathology, is essential. However,
genetic testing has an increasing role in the diagnostic
armamentarium:9 for example, conﬁrming clinical diagnosis,
establishing inheritance patterns, differentiating heteroge-
neous disorders, determining appropriate treatment, guiding
decisions about family planning, determining the cause of
unexplained familial renal disorders, identifying risk factorsKidney International (2017) 92, 796–808for recurrence in kidney transplantation, evaluating family
members’ suitability for kidney donation, and prompting
evaluation for extrarenal features (Table 1).10–12
Genetic testing can play an essential role in evaluating
children and young adults and thus should be considered when
the clinical phenotype does not suggest a clear diagnosis.9
The role of genetic testing in adults is generally more limited.
However, for those suspected to have a genetic disease, such as
X-linked Alport syndrome, testing can conﬁrm diagnosis and
establish inheritance patterns.13 In addition, some patients
view genetic testing as important for family planning, under-
standing their disease, and contributing personally to disease
research. Therefore, practitioners who treat adults with rare
kidney diseases should be knowledgeable about the modalities
of genetic testing, and all patients should be informed that
genetic testing is available when applicable.
For some patients, such as those with nephrotic syndrome
and urogenital malformations, genetic testing can be justiﬁed
based on minimal phenotypic information. Testing should be
considered when the index of suspicion for a given disease is
high and the patient would otherwise be exposed to invasive
procedures, or to ineffective or costly treatment with side effects
(e.g., children with steroid-resistant nephrotic syndrome).14
The decision to perform genetic testing should be collabora-
tive, with input from the nephrologist, clinical geneticist, genetic
counselor, genetic lab specialist, the primary care physician, the
patient, and his or her caregivers. With decreasing turnaround
times, genetic testing is increasingly becoming an important
contributor to clinical decision making.9
Presymptomatic genetic screening
In the context of genetic disorders, nephrologists should serve
as advocates for patients and their children, always respecting
each patient’s religious beliefs, cultural perspectives, and au-
tonomy in decisionmaking. Patients with any genetic diagnosis
should be counseled about reproductive options, including
germ cell donation, prenatal diagnosis, and preimplantation
genetic diagnosis.15 Nephrologists should collaborate with
trained clinical geneticists and genetic counselors to provide
information and recommendations. In children at risk for a
dominantly transmitted disorder, such as autosomal dominant
polycystic kidney disease, presymptomatic genetic testing
should be considered only if obtaining the information has
potential beneﬁts for managing emergent symptoms or pre-
venting complications.12 When there are no prevention or
treatment options available, many factors should be considered
before proceeding with testing, including type of disease, age
andmaturity of the child, and family’s cultural background and
resources. All patients should be counseled regarding the ways
in which a genetic diagnosis could hinder their ability to obtain
health or other types of insurance.16
Implementing access to diagnostic services in low-income
regions
Access to clinical expertise and genetic testing in resource-
poor countries may be limited. However, telemedicine can797
Table 1 | Sample case vignettes
Diagnostic challenges: Usefulness of genetic testing
An 8-month-old girl presents with failure to thrive, polyuria, polydipsia, and frequent vomiting. She is clinically dehydrated. Her height is at the 5th percentile.
Normal birth weight is mentioned. Blood analysis reveals hypokalemia, metabolic acidosis, hypophosphatemia, and hypocalcemia. Urinalysis reveals loss of
amino acids, potassium, bicarbonate, calcium, phosphate, glucose, and b2-microglobulin. There is no family history of kidney disease.
The most frequent cause of renal Fanconi syndrome in children is cystinosis. However, other metabolic diseases (tyrosinemia, galactosemia, glycogen
storage diseases), Wilson disease, Dent disease and Lowe syndrome should also be considered in the differential diagnosis of the renal Fanconi
syndrome. Some cystinosis patients initially present with atypical manifestations, such as metabolic alkalosis, and are initially diagnosed as Bartter
syndrome or nephrogenic diabetes insipidus. An early start of cysteamine therapy, which acts by lowering the intracellular accumulation of cystine, has
an important impact on the clinical outcome of patients with cystinosis, justifying an early diagnosis. The current gold standard for the diagnosis of
cystinosis is the detection of elevated cystine levels in white blood cells. Molecular testing of the CTNS gene is well-established and reveals 95% of
disease-causing mutations. (See Langman et al.10)
Challenges of transitioning children
A 16-year-old patient with a diagnosis of classic Bartter syndrome (mutations in CLCNKB) presents with cramps and muscle weakness. He is clinically
dehydrated. Kidney function is normal, but potassium level is at 2.0 mmol/l, magnesium is 0.4 mmol/l, bicarbonate 35 mmol/l. The patient was followed at
the tertiary hospital until age 13 years, but he was then lost for follow-up. He is now living with his mother and has difﬁculties in school. He knows about the
potassium and magnesium supplements, but he does not like to take so many pills. Indomethacin and spironolactone were used in the past but they were
stopped a few years ago. The patient feels generally ﬁne and does not understand why he is so weak.
Individual management of patients with salt-losing tubulopathies has been advocated, with particular emphasis on education about the disease
mechanism and importance of salt repletion and supplemental therapy. Side effects should be discussed, in particular abdominal pain and diarrhea
induced by magnesium salts and gastric irritation from potassium chloride. Physicians should also be attentive to other factors that could hamper
adherence to the supplements, including socioeconomic difﬁculties, lack of reimbursement, transition period to adulthood, work conditions, and such.
The transition phase between pediatric and adult care is particularly important. (See Blanchard et al.11)
Utility of Specialized Centers
An 8-month-old child presents to the emergency department with seizures. The clinical exam shows patches of light-colored skin on the trunk. Computed
tomographic scanning reveals multiple calciﬁed subependymal nodules in the brain. A diagnosis of tuberous sclerosis is made. Subsequent investigations
involve specialized neurology, dermatology, nephrology, ophthalmology, cardiology, and pulmonary consultations. The father had a history of childhood
seizures. He also presented adenoma sebaceum lesions along the nose, an ungula ﬁbroma on the left foot, an area of pigmented, thick leathery skin on the
lower back, and subependymal nodules on the brain computed tomographic scan.
Current consensus supports the value of a multidisciplinary team approach to care, with all relevant specialties provided in 1 center or clinic to patients
presenting with multisystemic disorders, including tuberous sclerosis and autosomal dominant polycystic kidney disease. These beneﬁts include access
to educational material about clinical manifestations, the opportunity to meet other patients with the same rare conditions, information about current
research studies, and, most importantly, substantial shortening of the odyssey incurred by multiple clinic appointments and fragmented care. (See
Chapman et al.12)
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in rare kidney diseases. Local strategies for genetic testing can
include mini-gene panels for a set of disorders, for example,
focal and segmental glomerulosclerosis, or direct tests for
population-speciﬁc variants or founder mutations. These
approaches can reduce costs associated with genetic testing
and the requisite bioinformatic analyses.MANAGING DECLINE IN KIDNEY FUNCTION
Measurement and treatment
Glomerular ﬁltration rate (GFR) should be assessed in
accordance to the 2012 KDIGO CKD Guideline and in pe-
diatric settings, with age-appropriate equations.17–20 GFR
estimation by creatinine (e.g., Chronic Kidney Disease
Epidemiology Collaboration [CKD-EPI] creatinine, Schwartz,
full-age-spectrum equation) may be misleading in patients
with abnormal body mass. In rare diseases with reduced
muscle mass or altered body habitus, the use of other for-
mulas (e.g., CKD in Children [CKiD], Filler, CKD-EPI cys-
tatin-C) or actual measurement of GFR may be advisable.21–23
Currently there is inadequate information regarding the
ability of GFR estimating equations to capture actual GFR
during the transition from adolescence to adulthood.798Rare genetic disorders typically require speciﬁc therapies
targeted to the speciﬁc disease pathophysiology. For instance,
renin-angiotensin-aldosterone system therapeutic blockade,
which is commonly used when there is proteinuria in the
context of progressive decline in GFR,24,25 is not applicable in
proximal tubular disorders, where albuminuria results from
impaired tubular albumin uptake rather than glomerular
injury. Moreover, in salt-wasting disorders, renin-angiotensin-
aldosterone system blockade may be harmful by compounding
hypovolemia and low blood pressure. Contrary to common
CKD management, use of nonsteroidal anti-inﬂammatory
drugs in certain polyuric tubular disorders may be indicated
and may even be renoprotective. Similarly, dietary salt re-
striction, while advised in hypertensive disorders, is likely
harmful in salt-wasting disorders. There is no evidence that
protein restriction should be different in rare versus more
common kidney diseases. Protein restriction is not recom-
mended in young children as it may affect growth.26
Monitoring patients for complications
Algorithms to monitor patients for the development of renal
and extrarenal complications are speciﬁc to each rare disease,
based on the nature of the pathology, and the rate of CKDKidney International (2017) 92, 796–808
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the potential speciﬁc complications and be able to discuss
them with patients and their caregivers. A multidisciplinary
approach, ideally with assistance from “Specialized Centers”
(also designated as Centers of Excellence/Expertise/Reference
in some jurisdictions, see Table 2)27 may optimize monitoring
and treatment of extrarenal complications. Finally, the deci-
sion about whether to monitor for complications that have no
bearing on clinical management (e.g., uterine abnormalities
that occur in patients with HNF1B mutations) should be
jointly considered by patients and their caregivers.
Improving standardization and access of optimal care
For rare diseases that lack treatment guidelines, establishing
clear protocols based on available publications or expertTable 2 | Standards and quality criteria for Specialized Centers (
some regions)
Standard
Comprehensive care
Renal and extrarenal care speciﬁc for the disorder
Genetics, including genetic testing
Dietetics
Psychosocial support
Coordinated by dedicated team leader
Expertise
Care is coordinated by a multidisciplinary team with relevant
expertise in the disorder
Clinical trials
Patients should be offered the opportunity to participate in clinical
trials relevant to the speciﬁc disorder
Education
Creation and distribution of information material for patients, fam-
ilies, and professionals, as well as education and training
Patient involvement
Direct patient involvement to ensure center serves the needs of the
patient
Facilitate transition from pediatric to adult care
Quality criteria
Established through a formal and transparent process based on deﬁned
criteria
Should directly involve relevant patient organizations
Performance metrics should be made easily and publicly available so
patients can identify the best available center for their condition
Improvement in care through standardized assessment and treatment
Financial implications
For additional information, see European Union Committee of Experts on Rare Disease
Kidney International (2017) 92, 796–808opinion can provide a basis for standardizing care. Treatment
guidelines should be developed by disease experts in part-
nership with patient organizations and modiﬁed as additional
data become available. Retrospective analysis of databases or
prospective trials or both can aid in determining the effec-
tiveness of various approaches to treatment. Specialized
Centers and networks linking these centers can accelerate the
development of treatment protocols.28,29 Developing practical
biomarkers for speciﬁc diseases could also improve stan-
dardization of care.
Access to optimal care is critical for the best possible out-
comes in patients affected by rare diseases. Governments, other
payers, and industry should ensure that all effective treatments
are available to patients worldwide. Patient organizations have
an important role in advocating for access to affordable,also known as “Centers of Excellence/Expertise/Reference” in
Metrics for assessment
Availability of ancillary services and nonrenal specialties needed for the
speciﬁc disorder
Publication record, number of patients with speciﬁc disease treated
Involvement in clinical trials for the speciﬁc disorder (if any)
Availability of informational material, courses, lectures, and training
Involvement of patients and patient organizations in establishing and
managing the center
Provision of multidisciplinary age-appropriate support services
Desired goals
Access to centers should be facilitated for every patient with the
established or suspected speciﬁc diagnosis
Referral should be timely and may require changes in existing medical
care models
Care should be provided in cooperation with—rather than in place of—
the patient’s local medical team
Health economic and patient-reported outcomes should be developed
Promoted by patient organizations
Increased empowerment of individual patients
Creation of online communities
Up-front ﬁnancing versus long-term cost reduction
s.27
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Centers. In geographic regions or countries without such
centers, partnerships between local practitioners and center
specialists in other regions or countries should be developed.
Transitioning from pediatric to adult care
A well-designed process of transition from pediatric to adult
nephrology health care systems is crucial.30–33 Psychosocial
support, management of potential extrarenal complications,
and genetic and reproductive counseling are all potential areas
of need for children maturing into adulthood. Specialized
Centers may be the optimal vehicle to provide the relevant
support and guidance during the transition period (Table 1).
The age at which a patient makes the transition from pe-
diatric to adult care varies between and within countries. For
example, in Singapore, the age of transition is 12 years,
whereas in the USA, patients in their 20s can still be in the
transition process. Transitioning patients between the pedi-
atric and adult centers should allow sufﬁcient time to prepare
patients and caregivers and include overlap between the care
teams through the transition to minimize the risk of non-
adherence to treatment that increases during adolescence and
young adulthood.34,35 Decisions about transition timing
should be predicated on patient-speciﬁc factors, such as
growth and maturity, rather than at a universally applied age.
Transition readiness should also be assessed as low transition
readiness predicts negative health outcomes.36 For patients with
cognitive impairment, ongoing special support may be necessary.
It is also important to educate patients about kidney
replacement therapies (e.g., dialysis, transplantation) early in
the disease course. Family members who wish to serve as
potential kidney donors may need to undergo genetic and
clinical screening, and patients and their families should be
made aware of recurrence risk after transplantation.
CHALLENGES IN CLINICAL STUDY DESIGN
Research in rare kidney diseases is difﬁcult for several reasons,
including limited sample sizes, the need for long duration of
follow-up, and the paucity of outcome measures.
Study design considerations
Although rare diseases by deﬁnition involve small numbers of
patients, applying good statistical methods in study design
should be independent of disease prevalence. Therefore,
design and sample size for rare disease studies should use
methods driven by the disease pathophysiology and natural
history, the outcomes measured, and the mechanism of action
and anticipated effect size of any intervention. New strategies
have been developed for maximizing information obtained
from a limited number of patients by using innovative trial
designs.37–40 Table 3 presents a variety of possible trial designs
along with a summary of their advantages and disadvan-
tages.40 Offering children the opportunity to participate in
clinical trial programs and entering both pediatric and adult
patients into studies that evaluate the mechanism of drug
action or an age-independent outcome measure or both may800be more efﬁcient than performing 2 studies would be. If
children are to participate in studies that include adults, age-
dependent toxicities should be considered.
Recruiting incident patients with rare diseases can be
particularly challenging. Prognostic and predictive enrich-
ment strategies employing clinical, biomarker, or genetic in-
formation can inform study design.41
Drug approval studies in patients with rare diseases should
address disease entities deﬁned by common pathophysiolog-
ical mechanisms, and extrapolation within a given disease
across age groups may be acceptable under strictly deﬁned
circumstances.42
Although observational data cannot replace randomized
controlled trials, such studies can provide helpful natural history
and safety information valuable for designing future studies.
Ethical accountability in trial design and reporting
Patient insights and input are essential for designing clinical
trials. Patients should be fully and independently informed of
trial options and should be made aware of trial registries such
as ClinicalTrials.gov to search for ongoing trials.
In studies of new treatments for rare diseases, placebos are
only justiﬁed for addressing safety and efﬁcacy, for example,
when there is no existing treatment or if the novel treatment
is being added-on to an existing treatment (e.g., Patti et al.43).
Participants who receive successful treatment in clinical trials
should be offered the opportunity to continue the treatment
after the trial has concluded, at least until it becomes
commercially available. Clinical trials results should be made
available publically and to all participants.
Outcome measures
There is a paucity of data about whether measured GFR
(mGFR) and estimated GFR (eGFR) are comparable in
capturing longitudinal changes in GFR. Due to small popu-
lation sizes in rare kidney diseases, mGFR is ideal.44,45
However, estimating rather than measuring GFR is generally
more practical, given the logistical challenges related to the
small number of patients per site. In choosing between eGFR
and mGFR, the range of GFR in the patients to be studied
should be taken into account. eGFR is less accurate in deter-
mining GFR changes in CKD stages G1 and G2 versus stages
G3a/G3b and G4. This limited accuracy may be partially
compensated for by frequent measurement and use of data-
smoothing technologies (Supplementary Figure S1).46–48
While the start of kidney replacement therapy is an
appropriate hard endpoint for kidney disease populations, the
lack of standardized criteria for starting kidney replacement
therapy is an issue for clinical research both in common and
rare kidney diseases.
Proteinuria reduction may be an appropriate surrogate
endpoint, depending on the pathophysiology and predomi-
nant clinical manifestations of a speciﬁc disease (e.g., hered-
itary podocytopathies). In tubulopathies, effects on losses
of water, electrolyte, and tubular proteins could be considered
as endpoints. Measurements of such losses should beKidney International (2017) 92, 796–808
Table 3 | Examples of study designs and their applications in rare kidney diseases
Design type/subtypea Short description Key advantages Key disadvantages
Single arm All patients receive the same
treatment; no control arm
All patients receive treatment; no risk
to get placebo; can help with
recruitment
No concurrent (or randomized) control
subjects; risks of various forms of bias
Cohort study Follow a group of patients
“exposed” to an agent
(treatment) and monitor their
subsequent health outcomes;
possibly compare with historical
control subjects
Could be useful when a treatment
has become accepted as
standard of care, but no formal
evaluation has taken place
High chance of selection and recall bias;
generally more useful for following up
adverse effects, rather than efﬁcacy effects
Stepped-wedge design Groups of patients are all given a
new treatment at different points
in time (e.g., a new group added
once a month or once a year)
All patients receive treatment; no
risk to get placebo
Possibly a long wait for some patients to
get treatment; some ambiguity over
quality of control data
Multiarm trials Studies where >1 treatment (or 1
treatment and a control/placebo)
are studied and compared
Usually randomized and concurrent
control data, so avoiding many
forms of bias
Few disadvantages, unless inefﬁcient
because better alternatives exist
Crossover Patients receive >1 treatment, one
after the other
Within-subject variability usually
less than between-subject
variability, so studies can be
smaller; every patient has a
chance to get multiple
treatments
Not useful for treatments that change the
course of disease; not useful for
treatments that cure; not useful in
mortality studies; not suited for drugs
with very long half-lives; each patient
has to commit to being in the trial longer
than most other designs
AB/BA design The most common type of
crossover design; patients either
receive treatment “A” followed by
treatment “B”, or treatment “B”
followed by treatment “A”
Simple design; easy to understand
and implement; generally allows
smaller sample size than many
other designs
As with crossover designs in general
Latin square Design for $3 treatments to be
tested in a crossover design
Can compare multiple treatments in
relatively few patients
As with crossover designs in general
Risks confounding treatment effects with
order in which they are given
Youden square Design for $3 treatments to be
tested in a crossover design
Can compare multiple treatments in
relatively few patients; each patient
in the study for less time than Latin
square because not all treatments
are tested in all patients
As with crossover designs in general;
randomizationandanalysis canbe complex
Williams square Design for $3 treatments to be
tested in a crossover design; it is
balanced for carryover effects
from one treatment to the next
Can compare multiple treatments in
relatively few patients
As with crossover designs in general;
randomization, analysis and
interpretation can be complex
Before–after design Patients are monitored (in a trial
setting) while off treatment and
then switched to be on treatment
and followed up further
Every patient knows they will
receive treatment; helps with
recruitment; simple to implement
Risk of bias if disease changes naturally
over time
N-of-1 Each patient serves as their own
control and is randomized to
receive different treatments
Highly applicable to ﬁnd the “best”
treatment for a particular patient
Lacks generalizability of conclusions from
one patient to another
Parallel groups Patients are randomized to receive
only 1 of $2 treatments
Very simple design; fewer potential
pitfalls than many of the
crossover designs; generally good
at avoiding bias
Can be less efﬁcient than many of the
alternative options
Factorial More than 1 treatment, and
combinations of treatments are
tested in 1 trial
Very efﬁcient; “2 (or more) trials for
the price of 1”
Every patient must be eligible to receive
any of the treatments (and combinations
of them); risks and difﬁculties of analysis
when unexpected interactions appear
(Continued on next page)
S Aymé et al.: Common elements in rare kidney diseases: KDIGO conference report KD IGO execu t i ve conc lu s i ons
Kidney International (2017) 92, 796–808 801
Design type/subtypea Short description Key advantages Key disadvantages
Basket study Multiple treatment options are
compared for 1 patient
population (1 condition)
Very efﬁcient; “multiple trials for the
price of 1”; new treatments can
enter the trial at any time, and
treatments shown to be
ineffective can be dropped at any
time
Uncertainties about appropriate control
data and possible changes in types of
patients over time
Umbrella study A single treatment is tested in
multiple conditions
Efﬁcient for trial logistics; single
infrastructure established
Potentially complex protocol unless all
conditions being considered need
treating in a very similar way
Covariate-adaptive A method to balance treatment
groups for baseline demographic
and prognostic factors
Excellent at maintaining balanced
groups, particularly when there
are too many to use simple
stratiﬁcation
Controversial in terms of validity and
analysis
Response-adaptive A method to skew allocation to
treatments toward the treatment
showing most promise of
superiority
Ethically very attractive; ensures
most patients receive what is
expected to be the best
treatment
Complex to manage and analyze; requires
relatively short-term endpoints
Randomized withdrawal A randomized trial where all
patients receive active treatment,
then some of the “responders”
are randomized to continue that
treatment and some are
randomized to stop
Ensures as many patients as
possible can beneﬁt from the
treatment
Not applicable for treatments that change
the course of disease; not applicable for
treatments that cure disease, or if
mortality is the endpoint
Adaptive designs A wide variety of possible designs
where some (potentially any)
aspect of the design can be
changed part way through the
study
Extremely ﬂexible in terms of what
can be changed—almost no
limits
Complex to design and analyze; often
difﬁcult to eliminate bias
Sequential design Usually a parallel group design
where interim analyses are
included to potentially stop the
trial early if convincing evidence
of efﬁcacy or harm are
established
Prevents trial running “too long”
when sufﬁcient evidence (usually
of efﬁcacy) is established
Adds complexity and need for data
monitoring committee; not useful for
trials with fast recruitment and slow-to-
reach efﬁcacy endpoints
Interim analysis Usually meant as an efﬁcacy
analysis in a sequential trial
Allows trial to be stopped early
when evidence of efﬁcacy or
futility is established
As with sequential designs in general
Futility analysis An interim analysis designed with
the intent to establish whether or
not a trial can potentially meet its
objectives
Allows early stopping if a trial is very
unlikely to meet objectives; saves
resources
As with sequential designs in general
Sample size reassessment Recalculating how many patients
are needed in a study while the
study is ongoing. Usually done on
blinded data
Allows check on original sample
size assumptions and correction
(if necessary); if done on blinded
data, no data monitoring
committee is needed
Planning (timelines and budget) cannot be
ﬁxed in advance
Superiority design A trial where the objective is to
show one treatment is better (in
efﬁcacy terms) than another, or
better than placebo
Clear interpretation of results;
obvious beneﬁt in terms of
patient outcomes
Can require very large number of patients
when established treatments already
exist
Equivalence design A trial where the objective is to
show one treatment has the
same level of efﬁcacy (within a
small tolerance) as another
Usually only of interest to expedite
regulatory approval of different
dosage forms of an established
medicine
Often need very large sample sizes;
difﬁculty in agreeing on an accepted
margin of tolerance to deﬁne
“equivalent”; ambiguity of interpretation
if no placebo group is included
Table 3 | Examples of study designs and their applications in rare kidney diseases (Continued)
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Design type/subtypea Short description Key advantages Key disadvantages
Noninferiority design A trial where the objective is to
show one treatment is no worse
than another (within a small
tolerance) but usually in the
context of having some other
beneﬁt (e.g., better safety or ease
of use)
Usually needs fewer patients than a
similar superiority trial; obvious
ethical preference of not using a
placebo control
Difﬁculty in agreeing on an accepted
margin of tolerance to deﬁne
“inferiority”; sometimes ambiguity of
interpretation if no placebo group is
included
Enrichment design A study that uses a run-in period to
select patients most likely to
respond to treatment and then
randomizes those to treatment or
control
Needs fewer patients randomized
than a similar study not using
enrichment
Limited applicability of results to a wider
population
Cluster randomized design A randomized trial where individual
patients are not randomized, but
groups of patients (e.g.,
households or villages) are
randomized
Good for infectious diseases and
public health policy trials
Ethical problems of informed consent;
while relatively few clusters may be
needed, total sample size (¼ no. of
clusters  average cluster size) can be
very large
Repeated measurements design A study where patient efﬁcacy
outcomes are recorded and
analyzed at multiple time points
More efﬁcient use of patients; more
data collected per patient can
allow some reduction in number
of patients needed
Analyses can be complex; relevance of
questions answered by the analyses
needs very careful discussion and
agreement
Bayesian design A formal (mathematical) way of
combining data from previous
trials and other experience with
data from a current trial
Sometimes easier interpretation of
results; there may be some
beneﬁt in not treating results
from a study in complete
isolation
Still controversial, so may be harder to gain
acceptance of study conclusions;
difﬁculty on agreeing how relevant past
data and experience are to the current
trial
aMany features of study design can be used in a variety of combinations (e.g., interim analyses with factorial designs, cluster randomization with crossover or parallel groups
designs, repeated measures designs, and Bayesian designs).
For additional information, see International Rare Diseases Research Consortium.40
Table 3 | (Continued)
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as polyuria, physical functions (e.g., muscle strength, fre-
quency of muscle cramps, headaches), and longitudinal
growth in children (Supplementary Table S1).
Many rare kidney diseases are associated with primary or
secondary neuropsychiatric consequences. Measurements of
cognitive, psychosocial, and developmental changes can be
used in the assessment of clinical trial outcomes in children
and adults. Patient-reported outcome measures (PROMs)
should be incorporated into clinical trials and registries of
rare kidney diseases, at least as adjuncts to clinical endpoints.
A limited set of kidney disease–speciﬁc PROMs have been
deﬁned (KD quality-of-life),49,50 and further speciﬁc PROMs
for adult and pediatric kidney diseases, such as polyuria and
physical functions, will become validated in the future, taking
PROMs beyond quality-of-life measures.
Shared interests in pharmacologic research
Collaboration and partnership between academia and in-
dustry in designing, conducting, analyzing, and publishing
results of clinical trials as well as sharing data from clinical
trials should be encouraged. Regulatory authorities should
promote the use of both independent studies and industry-
sponsored studies in applications for drug approval. In rare
diseases, competing trials that are performed on small cohortsKidney International (2017) 92, 796–808can slow the progress of research. Therefore, collaboration
should be encouraged between trialists and trial groups to
accelerate and maximize the information obtained.
TRANSLATION OF RESEARCH TO CLINICAL CARE
Translation from research to care depends on policies, insti-
tutional contributions, widespread use of instruments and
standards, and training of providers and patients.51,52
Specialized Centers, registries, and biobanks
Specialized Centers play key roles in translational medicine. In
Europe, the scope, mission, and designation procedures for
such centers have been deﬁned and can serve as a model for
other areas.53 Connecting these centers with research groups
and patient advocacy groups, nationally or internationally,
through shared registries or biobanks, research collaboration,
meetings, training, and exchanges is vital for distributing
expertise and advancing knowledge.54 Registries and biobanks
are key instruments for research and development.55 Quality
data repositories accelerate clinical research, facilitate collabo-
ration with industry, and provide data to regulatory or reim-
bursement bodies while avoiding duplication of efforts and
wasting of resources. Because data accessibility depends on
how data are stored, managed, and shared, toolboxes and
platforms must be developed for establishing and managing803
KDIGO execu t i ve conc lu s i ons S Aymé et al.: Common elements in rare kidney diseases: KDIGO conference reportregistries. As an example, the Clinical Data Interchange Stan-
dards Consortium has generated therapeutic area standards,
including those for autosomal dominant polycystic kidney
disease, that can be emulated.56,57 Additional organizations
working in this area are listed in Supplementary Table S2.
Strategies for the development of non-industry-driven regis-
tries have also been outlined recently.1 Improved collaborative
efforts by scientiﬁc societies and patient organizations to
integrate such initiatives, rather than creating competing ones,
should be encouraged.
Practical guidance for establishing rare disease registries is
also outlined in Table 4.58,59 In regions where there may be
more patients with rare, recessive diseases, there are oppor-
tunities for increasing participation in translational research
(Supplementary Table S3). Similarly, the establishment of
biobanks can provide widespread access to various samples
types, which in turn enable the development of adapted cell
and animal models to better understand disease pathophysi-
ology, screen for new drugs, and generate relevant in silico
models to identify new therapeutic targets.
Instruments and standards
Informed consent. Lengthy, dense informed consent
forms can be a barrier to patient participation in clinical trials
or registries. Consent forms should be designed to be quickly
and easily understood while allowing maximal use of data and
samples. Sharing approved consent forms may accelerate
regulatory approval. Current efforts by the International Rare
Diseases Research Consortium (IRDiRC) to create an elec-
tronic universal consent form for research in rare diseases
should be supported by all stakeholders.60
Standards of care. Standards of care are lacking for in-
dividual rare kidney diseases. Standards should address all
aspects of each disease, be developed with input from patients
and relevant providers, and be applicable in low-income
countries. These standards of care must be published and
available online. Patient organizations and clinicians shouldTable 4 | Recommendations for establishing rare disease
registries
 Establish as early as possible, even before potential drug development.
 Conceive and develop with input from academic teams and patient
organizations.
 Apply a bottom-up approach when setting up and running registries.
 Do not request clinicians to register their data twice (they are too busy).
 Use existing computerized systems at clinical level or establish a clinical
level system.
 Make systems interoperable—use common phenome descriptors (Hu-
man Phenome Ontology) and use common nomenclature of diseases
(orpha codes).
 Provide open access to data.
Source: European Union Committee of Experts on Rare Diseases. EUCERD core
recommendations on rare disease patient registration and data collection, 5 June
2013. Available at: http://www.eucerd.eu/wp-content/uploads/2013/06/EUCERD_
Recommendations_RDRegistryDataCollection_adopted.pdf. Accessed February 3,
201758 and Gliklich RE, Dreyer NA, Leavy MB, eds. Registries for Evaluating Patient
Outcomes: A User’s Guide. 3rd ed. Report no. 13(14)-EHC111. Rockville, MD: Agency
for Healthcare Research and Quality (USA); April 2014.59
804develop lay versions of the standards with iterative updating
as appropriate.
Patient-reported outcome measures. PROMs help ensure
that interventions have effectiveness in improving functional
abilities that matter most to patients. The development of
PROMs requires investment and collaboration from all
stakeholders. Increasingly, regulatory bodies and payers are
seeking evidence that any given intervention improves $1
PROMs. To this end, IRDiRC has published recommenda-
tions for accelerating and validating PROMs for rare diseases
(www.irdirc.org).61,62 Likewise, the Patient-Centered Out-
comes Research Institute and Core Outcome Measures in
Effectiveness Trials initiatives have issued guidance for
creating and standardizing novel PROMs.
Providers and patients
Clinician training. A curriculum on the common features
of rare diseases should be disseminated in the form of tool
kits and webinars. Recommendations for the global assess-
ment and treatment of rare diseases should be summarized
and customized to ﬁt the needs of speciﬁc rare kidney dis-
eases and local settings. Professional societies, including the
International Society of Nephrology, as well as local foun-
dations and regional committees should serve as training
resources.
Promoting awareness of the larger community. To increase
general awareness, World Kidney Day should focus on rare
kidney diseases as 1 of its yearly themes. Communities should
also be educated on issues important to patients, including
the prohibitively high cost of certain drugs. Relevant stake-
holders should create and take advantage of lobbying
opportunities.
Patient empowerment. Patients are partners in their own
care, but they need to be trained to fully deliver on their
implicit potential. For example, Summer School, an annual
training program sponsored by EURORDIS–Rare Diseases
Europe (www.eurordis.org), an alliance of more than 700 rare
disease patient organizations, builds capabilities among re-
searchers and patients in the area of medicine development.
PROVIDING PRACTICAL AND INTEGRATED PATIENT SUPPORT
Persons with long-term health conditions typically manage
symptoms and treatments on their own or with their families
and have very limited in-person contact with a health care
professional. Therefore, patients should be supplied with
written materials, websites, and checklists to serve as a
continuous resource outside of their provider visits. Although
there continues to be unmet needs regarding patient and
caregiver support (Supplementary Table S4),31 there are
many potential avenues for providing support (Table 5,
Figure 1).63
Psychological support for patients and their families
The psychological impact of being diagnosed with an
inherited kidney disease is different for every patient and can
vary over time with disease progression.64 Patients and theirKidney International (2017) 92, 796–808
Table 5 | Approaches to helping patients in health care
systems with differing resources
Health care systems
Well-resourced Low-resourced
Early access to ﬁnancial support for
eligible patients. Provide patients
with help in navigating the
system.
Knowledge of available networks
and opportunities such as grants
or voluntary exchange programs
Multidisciplinary care
 Joined-up appointments
 Multimodal resources
 Face-to-face, groups, workshops
 Research, trials, registries
 Lots of liaison: teams, hospitals,
education, employer
Maximum use of technology and
links with Specialized Centers
 Engage routine resources
 Make as much information avail-
able as possible
 Engage key groups/systems already
available, such as church, commu-
nity groups and leaders, or schools
Information
 Websites
 Webinars
 Pamphlets
 Podcasts
 Films
 Audio
 Social media
Information
 Simple ﬁlm, audio and print in-
formation targeting visual or
auditory learners may be most
effective
Patient associations
 Involved at every level
 Provide support
 Research and development
 Registries
 Advice
 Financial
 Strategic as well as supportive
 Seek representativeness
Facilitate access globally to
information and learning
 Proactively seek connections
with groups or individuals afﬁli-
ated with Specialized Centers
Specialized
centers
Psychology
Health care
professionals
Ongoing care
Day-to-day
living
Compliance
Psychological
impact
Social
implicaons
Educaon
Transion to
adult care
Peer support/
connecon
Paent
organizaon
engagement
Family impact
Financial
implicaons
Pharmacology
Patient
Figure 1 | Issues surrounding patient care.
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depression.65 For children and adolescents, having CKD in-
creases the risk of developing depression and anxiety.66 The
psychological impact of having a chronic disease depends on a
complex interaction of risk and resilience factors that must be
considered by care providers.
Children, adolescents, and young adults with a chronic
illness are vulnerable to falling behind socially and
educationally, with potential deleterious impact on future
earning potential and a reduced quality of life. Typically,
education systems are not equipped to handle students
with chronic illnesses, thus disadvantaging these stu-
dents.67 Assisting patients with disease management and
providing treatment plans that minimize the impact on
daily living (e.g., home dialysis at night, grouping health
care appointments, addressing medication side effects)
help patients maintain a sense of normalcy. Treatment
adherence is particularly at risk in college-aged students,
warranting extra support.
Patients and their support systems may have different
needs at various stages of disease, including diagnosis, man-
aging symptoms or treatments, or managing transitions in
care from pediatric to adult health care systems.32,33 The
challenge to sustain lifestyle adaptations that affect diseaseKidney International (2017) 92, 796–808progression may require speciﬁc strategies to change an in-
dividual’s behavior and maintain these changes.
The health care community can take several steps to help
patients and families manage the psychological impact of
rare kidney diseases, including speciﬁc training on the
impact of mental health on a patient and his/her support
system, how to discuss mental health issues with patients
and their families, and how to assess speciﬁc needs and
integrate awareness of mental health into medical care
planning. Health care providers should also be counseled on
the importance of talking separately to patients and their
family members to distinguish individual versus familial
perspectives and needs.
Patients should be made aware of support groups, espe-
cially peer-to-peer groups that operate locally or more glob-
ally, including online support. Periodic psychological
assessments should be considered to determine whether in-
terventions are needed.
Patient organizations
Patient organizations can promote disease awareness and
education to inﬂuence health policy locally, nationally, and
internationally. Examples are lobbying for reimbursement
coverage for treatments, improved health care provisions, and
government assistance with life insurance for families with a
genetic disease. Patient organizations can be helpful in
encouraging patients to get more care, earlier. They can also
interact with clinicians, academia, industry, and government
and regulatory agencies to promote research,68 develop new
treatments, and implement risk-beneﬁt assessments.
The ﬁnancial impact of a chronic disease is considerable
and long-lasting for patients and their caregivers. Although
available ﬁnancial support varies considerably throughout
the globe, patient support organizations can be reliable
sources of information. Some patient organizations also805
Table 6 | Gaps in knowledge for future research
 How should genetic test results be reported? It can be difﬁcult to discern whether genetic variants are pathogenic, likely pathogenic, or of unknown
clinical importance. To facilitate better reporting of genetic tests, data sharing in the form of disease-speciﬁc variant databases such as the Human
Gene Mutation database (www.hgmd.org), ClinVar (www.ncbi.nlm.nih.gov/clinvar), and the Leiden Open Access Variation database (www.lovd.nl) may
be key. Centers conducting genetic testing should also examine any available guidelines, such as those from the European Molecular Genetics Quality
Network (http://www.emqn.org/emqn/Home) and the American College of Medical Genetics and Genomics (https://www.acmg.net). Can reports be
presented to include a clear conclusion regarding whether a pathogenic variant was absent or present, as well as the need for referral to a clinical
geneticist or genetic counselor?
 How can we determine the preferred method of genetic testing? Successful application of next-generation sequencing in diagnostic mutation
screening, using multigene, disease-speciﬁc panels, has been demonstrated for Alport syndrome, steroid-resistant nephrotic syndrome,
nephronophthisis, other renal ciliopathies, and tubulointerstitial kidney diseases. Beyond disease-speciﬁc next-generation sequencing panels, whole
exome sequencing and potentially whole genome sequencing may soon become part of routine molecular diagnostics in some countries, further
improving the diagnostic yield. For example, rapid whole genome sequencing (with whole exome sequencing and copy number variation analysis)
might be clinically useful in diagnosing neonates with unexplained kidney failure. How can the nephrology community and health economists
determine the cost-effectiveness of these various genetic testing approaches?
 What studies can be conducted to better understand the health risks of and potential for kidney donation for heterozygous carriers of
recessive mutations?
 Can we identify the best methods to estimate glomerular ﬁltration rate during adolescence? What are other innovative ways to improve
medication adherence in adolescents?
 How can adaptive designs be best used in small trials? Although the value of adaptive designs in small trials seems clear, the amount of infor-
mation available from a small trial may be insufﬁcient to reliably assess what features might best be adapted. This ranges from relatively simple
adaptations such as sample-size reestimation, to more complex adaptations such as changing doses, changing endpoints, changing comparator
groups, and such.
 How can fully Bayesian designs be made acceptable to all stakeholders? A great value of Bayesian designs might be the ability to incorporate
“informative” priors that can add more information to the data collected in a study. However, despite progress in how to elicit prior beliefs from
experts, different priors might legitimately be held by experts, patients, sponsors, and regulators. Without agreement on an acceptable prior by all
stakeholders, results of Bayesian analyses are likely to remain controversial.
 How can we better utilize biorepositories to advance diagnosis and treatment of rare kidney diseases? The use of biorepositories could advance
development of biomarkers for screening and assessments for kidney function, end-stage kidney disease, or treatment response. Biobanking that
includes samples from patients with rare kidney diseases should be encouraged on national and international scales. Biobanks should include
pretreatment urine and plasma specimens as well as serial samples of RNA and DNA over time. It is also imperative that specimens are linked to rich
phenotypic databases. With increased collaboration between different biorepository networks in the future, how can we resolve issues regarding
ownership of biobank material or speciﬁc usages that were not covered in the initial consent?
 What are some of the challenges for maintaining effective registries? Poor data quality, especially with long-term data collection done on a
voluntary basis with poorly deﬁned objectives, is such a problem. Would it be practical for registries to provide a minimum set of data for all
relevant patients and greater detail for a subset of patients? In addition, will jurisdiction laws from different countries hamper international
collaboration?
 What will the Specialized Center model look like in less developed countries?
 What studies can be conducted to better understand how the transition process from pediatric to adult be optimized for individual rare
kidney diseases?
 How can psychosocial factors be better assessed in patients to predict successful transitional readiness from pediatric to adult care?
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researchers.CONCLUSION
A common theme that emerged from the meeting is the
importance of collaboration in advancing care and research
for rare kidney diseases (Tables 2, 5, and 6). Improvements in
diagnosis and treatment depend on the collaborative in-
teractions among clinicians, patients, industry representatives,
regulatory agents, and government agencies to support
innovative approaches for diagnosis and management of
patients with rare kidney diseases.806DISCLOSURE
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